BRD0209 (BRD 0209)
BRD0209 (BRD 0209) Basic information
- Product Name:
- BRD0209 (BRD 0209)
- Synonyms:
-
- BRD0209 (BRD 0209)
- BRD0209
- 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-cyclopropyl-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)-
- (S)-3-Cyclopropyl-4,7,7-trimethyl-4-phenyl-2,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
- BRD0209/(S)-3-Cyclopropyl-4,7,7-trimethyl-4-phenyl-2,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
- BRD0209, 10 mM in DMSO
- (4S)-3-cyclopropyl-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one
- CAS:
- 1597439-87-6
- MF:
- C22H25N3O
- MW:
- 347.45
- Mol File:
- 1597439-87-6.mol
BRD0209 (BRD 0209) Chemical Properties
- form
- Solid
- color
- Light yellow to yellow
BRD0209 (BRD 0209) Usage And Synthesis
Description
BRD0209 is a highly selective and potent GSK3 inhibitor. BRD0209 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3).
Uses
BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases[1].
References
[1] Wagner FF, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016;11(7):1952-1963. DOI:10.1021/acschembio.6b00306
BRD0209 (BRD 0209)Supplier
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 86-571-88216897,88216896 13588875226
- sales@hzclap.com
- Tel
- 15907120073
- 1261789306@qq.com
- Tel
- 18096409024
- sales02@foreversyn.com
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com